Oxygen survey confirms TAM, supports Inogen bull thesis, says Piper Jaffray

Piper Jaffray analyst JP McKim believes his oxygen survey debunks a lot of the bearish arguments around the Medicare Claims data and supports his long-term Inogen bull thesis. That said, the survey did not give him a ton of confidence in near-term BTB results. While the analyst does not get the sense Q1 is going to be the snap back quarter like he expects Q2 to be, he argues that with the stock at $79, a lot of that is already reflected in the share price. Finally, as investors have been solely relying on the Medicare claims data for market sizing, McKim believes this survey provides another data point to confirm the market is large, still growing, and shifting to POCs. He reiterates an Overweight rating and $185 price target on the shares.

https://thefly.com/landingPageNews.php?id=2894896